Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation

Search Page

Filters

My NCBI Filters

Text availability

Article attribute

Article type

Publication date

Search Results

48 results

Filters applied: . Clear all
Results are displayed in a computed author sort order. The Results By Year timeline is not available.
Page 1
Interim safety and immunogenicity of COVID-19 omicron BA.1 variant-containing vaccine in children in the USA: an open-label non-randomised phase 3 trial.
Dixit A, Bennett R, Ali K, Griffin C, Clifford RA, Turner M, Poston R, Hautzinger K, Yeakey A, Girard B, Zhou W, Deng W, Zhou H, Schnyder Ghamloush S, Kuter BJ, Slobod K, Miller JM, Priddy F, Das R; ROVER Study Investigators. Dixit A, et al. Among authors: priddy f. Lancet Infect Dis. 2024 Mar 19:S1473-3099(24)00101-4. doi: 10.1016/S1473-3099(24)00101-4. Online ahead of print. Lancet Infect Dis. 2024. PMID: 38518789
Robust immunogenicity of a third BNT162b2 vaccination against SARS-CoV-2 Omicron variant in a naïve New Zealand cohort.
Lavender B, Hooker C, Frampton C, Williams M, Carson S, Paterson A, McGregor R, Moreland NJ, Gell K, Priddy FH, Wiig K, Le Gros G, Ussher JE, Brewerton M. Lavender B, et al. Among authors: priddy fh. Vaccine. 2023 Aug 31;41(38):5535-5544. doi: 10.1016/j.vaccine.2023.07.051. Epub 2023 Jul 27. Vaccine. 2023. PMID: 37516574 Free article.
Immunogenicity of BNT162b2 COVID-19 vaccine in New Zealand adults.
Priddy FH, Williams M, Carson S, Lavender B, Mathieson J, Frampton C, Moreland NJ, McGregor R, Williams G, Brewerton M, Gell K, Ussher J, Le Gros G. Priddy FH, et al. Vaccine. 2022 Aug 12;40(34):5050-5059. doi: 10.1016/j.vaccine.2022.07.009. Epub 2022 Jul 12. Vaccine. 2022. PMID: 35868948 Free PMC article.
Monitoring of Adverse Events in Recipients of the 2-Dose Ebola Vaccine Regimen of Ad26.ZEBOV Followed by MVA-BN-Filo in the UMURINZI Ebola Vaccination Campaign.
Nyombayire J, Ingabire R, Magod B, Mazzei A, Mazarati JB, Noben J, Katwere M, Parker R, Nsanzimana S, Wall KM, Sayinzoga F, Tichacek A, Robinson C, Hammoud N, Priddy F, Allen S, Karita E. Nyombayire J, et al. Among authors: priddy f. J Infect Dis. 2023 Jan 11;227(2):268-277. doi: 10.1093/infdis/jiac283. J Infect Dis. 2023. PMID: 35776140 Free PMC article.
Safety, reactogenicity, and immunogenicity of a 2-dose Ebola vaccine regimen of Ad26.ZEBOV followed by MVA-BN-Filo in healthy adult pregnant women: study protocol for a phase 3 open-label randomized controlled trial.
Karita E, Nyombayire J, Ingabire R, Mazzei A, Sharkey T, Mukamuyango J, Allen S, Tichacek A, Parker R, Priddy F, Sayinzoga F, Nsanzimana S, Robinson C, Katwere M, Anumendem D, Leyssen M, Schaefer M, Wall KM. Karita E, et al. Among authors: priddy f. Trials. 2022 Jun 20;23(1):513. doi: 10.1186/s13063-022-06360-3. Trials. 2022. PMID: 35725488 Free PMC article.
Measles immunity gap among reproductive-age women participating in a simulated HIV vaccine efficacy trial in Zambia.
Malama K, Tichacek A, Kelly H, Parker R, Inambao M, Sharkey T, Wall KM, Kilembe W, Price MA, Fast P, Priddy F, Allen S. Malama K, et al. Among authors: priddy f. Hum Vaccin Immunother. 2022 Nov 30;18(5):2066426. doi: 10.1080/21645515.2022.2066426. Epub 2022 Apr 21. Hum Vaccin Immunother. 2022. PMID: 35446726 Free PMC article. Clinical Trial.
Safety, pharmacokinetics and antiviral activity of PGT121, a broadly neutralizing monoclonal antibody against HIV-1: a randomized, placebo-controlled, phase 1 clinical trial.
Stephenson KE, Julg B, Tan CS, Zash R, Walsh SR, Rolle CP, Monczor AN, Lupo S, Gelderblom HC, Ansel JL, Kanjilal DG, Maxfield LF, Nkolola J, Borducchi EN, Abbink P, Liu J, Peter L, Chandrashekar A, Nityanandam R, Lin Z, Setaro A, Sapiente J, Chen Z, Sunner L, Cassidy T, Bennett C, Sato A, Mayer B, Perelson AS, deCamp A, Priddy FH, Wagh K, Giorgi EE, Yates NL, Arduino RC, DeJesus E, Tomaras GD, Seaman MS, Korber B, Barouch DH. Stephenson KE, et al. Among authors: priddy fh. Nat Med. 2021 Oct;27(10):1718-1724. doi: 10.1038/s41591-021-01509-0. Epub 2021 Oct 7. Nat Med. 2021. PMID: 34621054 Free PMC article. Clinical Trial.
Development and deployment of COVID-19 vaccines for those most vulnerable.
Koff WC, Schenkelberg T, Williams T, Baric RS, McDermott A, Cameron CM, Cameron MJ, Friemann MB, Neumann G, Kawaoka Y, Kelvin AA, Ross TM, Schultz-Cherry S, Mastro TD, Priddy FH, Moore KA, Ostrowsky JT, Osterholm MT, Goudsmit J. Koff WC, et al. Among authors: priddy fh. Sci Transl Med. 2021 Feb 3;13(579):eabd1525. doi: 10.1126/scitranslmed.abd1525. Sci Transl Med. 2021. PMID: 33536277 Review.
Cohort Profile: IAVI's HIV epidemiology and early infection cohort studies in Africa to support vaccine discovery.
Price MA, Kilembe W, Ruzagira E, Karita E, Inambao M, Sanders EJ, Anzala O, Allen S, Edward VA, Kaleebu P, Fast PE, Rida W, Kamali A, Hunter E, Tang J, Lakhi S, Mutua G, Bekker LG, Abu-Baker G, Tichacek A, Chetty P, Latka MH, Maenetje P, Makkan H, Hare J, Kibengo F, Priddy F, Landais E, Chinyenze K, Gilmour J. Price MA, et al. Among authors: priddy f. Int J Epidemiol. 2021 Mar 3;50(1):29-30. doi: 10.1093/ije/dyaa100. Int J Epidemiol. 2021. PMID: 32879950 Free PMC article. No abstract available.
48 results